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ABSTRACT
Insulin dependent diabetes mellitus (IDDM) is known to be one of the major risk factors for patient
survival after the development of end-stage renal failure (ESRF). Simultaneous pancreas/kidney
(SPK) transplantation has been pioneered by a number of units. The Westmead transplant program
has demonstrated that SPK transplantation yields a technically successful result in comparison to
the alternative of kidney transplantation alone. In Australian patients with IDDM and ESRF, the
treatment of choice is to undergo SPK transplantation before the need for dialysis and before the
development of severe neuropathy. Diabetic retinopathy must have been adequately treated by
laser photocoagulation and the ideal patient will be young and normotensive, with no pre-existing
carotid or femoral atherosclerotic plaque. This approach may, for a small proportion of patients
with ESRF and IDDM, return their prognosis to that of the non-diabetic.
Key words: Simultaneous kidney/pancreas (SKP) transplant, Diabetic complications, Diabetic neuropathy,
Diabetic retinopathy
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INTRODUCTION
Insulin dependent diabetes mellitus (IDDM) is known
to be one of the major risk factors for patient survival
after the development of end-stage renal failure (ESRF)
(1). It is on this background that simultaneous pancreas/
kidney (SPK) transplantation has been pioneered by a
number of units, as a strategy for improving prognosis
and reducing morbidity in dialysis dependent diabetics
and, as a step toward early treatment of diabetes, to
prevent the onset of the devastating secondary
complications.
The initial studies of clinical pancreas transplantation
were undertaken in Minneapolis with the first report in
1967 (2). The poor success rates in the early experience
inhibited development until the early 1980s when better
patient selection, cyclosporine immunosuppression, and
improved surgical techniques employing bladder
drainage of exocrine secretions, lead to measurable
success (3-6). The number of pancreas transplants
performed worldwide rose exponentially during the late
1980s as more centers, including the Westmead unit,
commenced SPK transplantation. During the 1990s
attention has turned toward transplantation of cadaveric
pancreas alone prior to the onset of renal failure and as
an additional procedure in diabetic patients with
12
Pancreas/kidney transplant outcome
functioning renal transplants (4). A small number of
centers in the United States have also embarked upon
living related segmental pancreas transplantation (7).
The Westmead Unit undertook SPK transplantation in
1987 and in the subsequent 12 years has transplanted
106 patients using a standardized approach to assessment,
transplantation and follow-up. In this review, we focus
on the outcome of these patients in terms of survival,
glycemic control and progression of the secondary
complications of diabetes. These analyses have been
undertaken using various cohorts of patients from the
total experience and have been performed progressively
during the past 5 years.
PATIENT ASSESSMENT
Between 1987 and 1997, 204 patients were referred for
assessment for SPK transplantation. All patients were
assessed by clinical history, physical examination,
ophthalmic examination, electrocardiogram, duplex
vascular ultrasound, peripheral nerve conduction studies,
routine biomedical, hematological and virological
parameters and finally by stressed cardiac nuclear
scanning. The cardiac scan of choice was initially
Thallium 201-Dipyridamole and more recently has been
Sestamibi - dipyridamole. Patients with abnormal
stressed cardiac scans proceeded to coronary
angiography and coronary revascularization if needed.
Patients deemed unsuitable for SPK were those with
irremediable coronary artery disease or severe peripheral
vascular disease with lower limb amputations (Table 1).
Referral patterns have changed during the period from
1987 to 1999, such that a very small percentage of
potentially eligible patients were referred for
consideration in the first few years. It can be seen,
however, that about one-third to a half of all Australian
IDDM ESRF patients being transplanted received SPK
in the mid 1990s (Fig. 1) . These patients are selected
from a larger pool of IDDM patients accepted onto
dialysis, most of whom are medically unsuitable for
transplantation.
TRANSPLANTATION TECHNIQUE
All patients were transplanted using the same technique
of intra-peritoneal pancreas transplantation with bladder
drainage of the exocrine secretions. In the first three
patients a button of duodenal tissue was anastomosed to
the dome of the bladder. In subsequent patients a segment
of donor duodenum was anastomosed side to side to the
dome of the bladder. Arterial and venous anastomoses
were to the iliac vessels on the right side with vascular
reconstruction using donor iliac vessels, required in most
cases. Conventional renal transplants were performed on
the left side, the first 12 being placed extra-peritoneally,
but in all subsequent patients the kidney was intra-
peritoneal.
Patient survival for all Australian patients was reported
in detail in 1996 and included a small number of patients
from three other hospitals performing one transplant each
and one hospital (Monash Medical Centre) performing
the remaining transplants (8). The outcome of these
patients, both in terms of patient survival and graft
survival was compared with diabetic and nondiabetic
recipients of renal transplants. The results of all
Australian kidney transplants in the years from 1980 to
1994 are shown in figure 2. In a multivariate analysis of
these data there were two independent predictors of
patient survival - pre-transplant dialysis (hazard ratio
3.0, CI 1.0-9.7) and pancreas transplantation (hazard ratio
0.48, CI 0.24-0.96) (8). The optimal situation of SPK
before the need for dialysis, occurred in 40% of recipients
Table 1. Outcome of  assessment  o f  pat ients  for  SPK
transplantation 1987-1997.
No %
Accepted and transplanted 86 42
Accepted and wait listed 29 14
Accepted, died waiting 3 1
Pending investigation and decision 23 11
Pending PAK or PTA 4 2
Refused for SPK 40 20
Assessed but Renal transplant alone 10 5
Patient withdrew 7 3
Not diabetic 7 3
Total 204
SPK = Simultaneous pancreas/kidney transplantation
PAK = Pancreas after kidney transplant
PTA = Pancreas transplant alone
Figure 1. Number of kidney and Westmead SPK transplants
performed in Australia in patients with IDDM, compared with the
total number of new IDDM patients with ESRF, between 1980 and
1997.
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of SPK transplants. Despite adjustment by inclusion in
the multivariate analysis of many of the obvious factors
that one might predict would cause selection bias (such
as age of recipient, and comorbid risk factors of smoking,
vascular disease, cardiac disease and donor factors such
as age), it is still likely that selection bias may have
influenced the better survival outcome of SPK recipients.
The survival of Westmead SPK patients is shown in
figure 3. It is slightly better than the overall Australian
experience (details not shown).
The causes of death were comparable to those
encountered in the general transplant population (Table
2), irrespective of the organ being transplanted.
Cardiovascular death, infection and malignancy result
from the patients' pre-existing cardiovascular status and
the use of immunosuppressants. Rigorous attention to
detailed assessment, early transplantation in uremic
patients before the need for dialysis, pre-transplant
surgical correction of cardiac disease, together with
control of risk factors for cardiovascular disease are
probably the only ways to minimize cardiovascular death,
while improved selectivity of immunosuppression may
eventually yield reductions in both infection and
malignancy.
Analyses of the survival of SPK patients in other centers
have similarly demonstrated beneficial results from SPK
compared with kidney transplantation. In the Netherlands
it has been possible to compare the outcome of patients
transplanted in two geographical areas, one with access
to SPK and one with little access (9). They found equal
survival in the two areas for patients on dialysis, but
transplanted patients' mortality was 50% lower in the
region employing SPK compared with the region not
using SPK. Similar analyses have been undertaken in
other populations in the United States (10-12), but all
conclusions are limited by the fact that there have been
no controlled trials of SPK compared to kidney
transplantation alone.
GLUCOSE METABOLISM
AFTER SPK
The function of the pancreas after transplantation is to
provide normoglycemia despite the influences of
corticosteroids, cyclosporine, weight gain and systemic
delivery of insulin. The fact that, despite the damage from
ischemia and rejection, so many patients remain without
the need for supplementary oral hypoglycemic agents
or insulin, is a testament to the functional reserve of the
pancreas. Routine follow-up of Westmead SPK patients
Figure 2. Actuarial graft survival of all Australian patients
transplanted with kidneys between 1980 and 1994, comparing non-
diabetics with type 1 IDDM patients receiving SPK or kidney
transplants alone, and type 2 diabetics receiving kidney transplants.
Figure 3. Actuarial patient, kidney and graft survival for patients
receiving SPK transplants at Westmead between 1987 and 1999.
Table 2. Causes of patient and graft loss after SPK at Westmead.
Cause N Months post-transplant
Patient death 15
   Cardiac 4 0, 6, 73, 82
   Cerebrovascular 3 3, 64, 81
   Infective 5 1, 4, 15, 43, 74
   Malignancy 3 5, 18, 75
Pancreas loss 18
   Preservation injury 3 0,0,0
   Thrombosis 12 0,0,0,0,0,0,0,1,1,2,4,5
   Acute rejection 1 0
   Chronic rejection 2 3,29
   PTLD 1 5
Kidney loss 3
   PTLD 1 5
   Chronic rejection 1 75
   Thrombosis 1 0
SPK = Simultaneous pancreas/kidney transplantation
PTLD = Post-transplant lymphoproliferative disease
14/15 patient deaths were with functioning pancreases
All patients who died had functioning kidneys at the onset of the
   terminal illness.
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has involved an annual glucose tolerance test with a
standard 75 g oral load of glucose after an overnight fast,
with measurement of blood glucose, insulin and C-
peptide levels for 180 minutes (13). In both univariate
and multivariate analysis of the factors affecting glucose
homeostasis we showed that there were a number of
determinants of both early and late pancreas function
(14). At 3 months the fasting glucose levels was in the
normal range for non-diabetic patients (4.7 ± 0.8 mmol/
L) and remained remarkably stable for 10 years of follow-
up. In contrast, fasting and stimulated insulin and C-
peptide levels were markedly elevated (Table 3). In the
univariate analysis, pancreatic function was shown to
be sensitive to pancreas ischemia, with impaired C-
peptide responses correlated with increased pancreas
anastomosis time. This was confirmed by the multivariate
analysis which identified prolonged donor ventilation,
kidney ischemia time and pancreas anastomosis time. In
addition, factors that impaired the 3-month pancreas
function were HLA mismatch, pancreas rejection and
increased body weight. Predictors of long-term pancreas
function were also examined in this study. Peripheral
insulin resistance was identified and correlated with time
after transplantation, prednisolone dose, serum urea,
calcium and albumin, body weight, and cyclosporine
dose. No relationships were found between endocrine
and exocrine function, emphasizing the difference
between rejection of exocrine tissue, found commonly
on biopsy, and rare histological involvement of islets in
acute rejection.
These data demonstrated that pancreas allograft function
provides excellent long-term glucose homeostasis, but
it is at the expense of peripheral hyperinsulinemia. It is
possible that portal delivery of insulin would have an
impact on circulating insulin levels, but the peripheral
insulin resistance demonstrated in our study may override
the importance of the delivery source of insulin. The
strong relationship between function and ischemia is a
warning that great attention has to be paid to avoiding
ischemic insults to the islets and also implies that isolated
islets may suffer similarly from sensitivity to ischemia.
The weak correlations with rejection testify to the large
pancreatic endocrine reserve and perhaps also to relative
resistance to rejection of the islets.
SECONDARY COMPLICATIONS
OF DIABETES AFTER SPK
The main just i f icat ion for  undertaking SPK
transplantation lies in the predicted effect that normal
glycemic control would have on the secondary
complications of diabetes. It could be hoped that
nephropathy in the renal transplant would not arise, that
retinopathy, neuropathy and vascular disease would
regress or stabilize and that the quality of life would
improve markedly. We set out to examine these questions
in a prospective and long-term manner, using an annual
review with a set follow-up protocol designed to collect
quantitative and qualitative data from all patients alive
following transplantation, whether or not the grafts were
functioning. This program has led to publication of a
number of studies to this point, as detailed below, with
major studies of nephropathy and quality of life changes
still to be undertaken.
Retinopathy
Diabetic retinopathy is known to be amenable to good
diabetic glucose control (15,16) and is an almost
universal accompaniment of diabetic end-stage
nephropathy (17). We have studied the course of
retinopathy for 10 years after SPK transplantation (18)
in 54 patients. Ten of the 108 eyes were blind at
transplantation and 79% had advanced retinopathy with
prior pan-retinal photocoagulation. Early post-transplant
vitreous hemorrhage occurred in 6.1% and was
associated with established active retinopathy. In the
long-term 76% of eyes remained stable, 14% improved
and 10% deteriorated, but this was not correlated with
the level of pancreatic function. Other studies of
retinopathy after SPK suffer from the same intrinsic
problem: severe disease is almost universal at the time
of transplantation and this over-rides any differences that
good glycemic control might exert. The study does
emphasize the importance of good control of active
proliferative retinopathy with laser therapy prior to
transplantation to reduce the risk of early vitreous
hemorrhage.
Neuropathy
Diabetic peripheral and autonomic neuropathy may lead
Table 3. Pancreas endocrine function 3 months after SPK
transplantation and the effect of histologically documented pancreas
rejection.
No pancreas rejection  Pancreas rejection
Episodes Episodes
Number 15 23
Body weight (kg) 63.3 ± 9.0 67.4 ± 11.2
GFR (ml/min) 54 ± 11.5 52.4 ± 15.6
Fasting glucose (mmol/L) 5.0 ± 1.0 4.4 ± 0.7
Fasting insulin (uU/ml) 26.2 ± 17.2 27.0 ± 17.8
Fasting C-peptide (µg/L) 4.7 ± 1.5 5.3 ± 2.2
AUC C-peptide (µgl-1 min) 1563 ± 572 1506 ± 514
Fasting insulin/glucose ratio 5.21 ± 2.81 5.84 ± 2.77
SPK = Simultaneous pancreas/kidney transplantation
GFR = Glomerular filtration rate
AUC = Area-under-curve
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to frequent and disabling symptoms. IDDM patients
undergoing SPK recently at Westmead had an average
of  25 years of diabetes and thus, by the time of
transplantation, usually had severe diabetic neuropathy.
This is complicated by the imposition of uremic
neuropathy, with 76% having been on dialysis for a mean
of 1.5 ±1.2 years (19). Neuropathy was studied by using
electrophysiological studies pretransplant and then
annually after transplantation in 53 patients for up to 8
years. A total of 254 studies were analyzed using
univariate and multivariate methods (19). The initial
nerve conduction was worse in the lower than upper
limbs, both improving after transplantation. The total
Nerve Conduction Score (NCS) improved by 12.9% over
the first 6 months and then stabilized, contributed mostly
by a 22.2% increase in conduction velocity (CV),
consistent with reversal of the effects of uremia (20,21)
(Fig. 4). Changes in the nerve amplitude were progressive
over the duration of the study, consistent with axonal
regeneration after SPK transplantation. The predictors
of immediate improvement in CV were younger recipient
age, shorter height and lower fasting insulin, but no
relationship was found with indices of renal function.
At 6 months the NCS was predicted by GFR, absence of
pretransplant dialysis, lower body weight and HLA
mismatch. In the longer term, however, the factors
influencing NCS were serum urea, body weight and
insulin resistance as measured by fasting insulin to
glucose ratio. Improvement in neuropathy was faster in
patients with better initial nerve function (Fig. 5), better
in sensory than motor nerves and in those who weighed
less.
The data from our study (20) and those from other units
(22,23) demonstrate quite clearly that, while reversal of
uremia is important for gaining immediate improvement
in neuropathy, sustained improvement with a trend
toward normalizing nerve conduction can be achieved
after SPK. A good outcome can only be expected in those
in whom the initial nerve damage is not severe, implying
that the mechanisms of severe diabetic neuropathy
involve irrecoverable neurone damage, perhaps by
fibrotic interruption of nerve regrowth. SPK
transplantation is therefore indicated before the onset of
severe neuropathy and rapidly deteriorating peripheral
neuropathy in a diabetic patient with chronic renal failure
would provide a reasonable indication for pre-emptive
transplantation.
Vascular Disease
Cardiovascular and cerebrovascular disease are the
leading causes of both morbidity and mortality in patients
who develop ESRF, no matter which renal replacement
therapy is used (24). The same diseases, exacerbated by
neuropathy, lead to death and disability in patients with
IDDM with normal renal function and account for most
of the excess mortality after renal transplantation (25).
There is, however, considerable evidence that the
pathology and pathophysiology of vascular disease are
different in the uremic and nonuremic populations
(26,27). Examination of the progression of vascular
disease after SPK transplantation is thus of considerable
importance in predicting long-term outcomes in this
group of patients.
Carotid and femoral doppler ultrasound examination are
both safe and relatively reproducible and we thus
undertook a prospective longitudinal study of SPK
recipients (28). A total of 765 studies were performed
either prior to transplantation or at annual intervals for
Figure 4. Nerve conduction studies in 44 patients followed for 6
years after SPK transplantation (19).
Legend: Time post transplantation in years. Triangle/dashed line =
Compound muscle action potential NCS. Cross/solid line =
Common peroneal nerve CV. Square/dashed line = Sensory nerve
CV NCS. Diamond/solid line = Motor nerve CV NCS. Normal value
for NCS is zero, a negative value indicating impairment.
Figure 5. Changes in total NCS after SPK transplantation,
stratified according to severity of the initial neuropathy: top quartile,
second best quartile and two worst quartiles combined (19).
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10 years after SPK transplantation in 82 patients. Carotid
plaque was present in 22.5% of patients before
transplantation and increased steadily to reach a
prevalence of 56.6% beyond 7 years post-transplant. The
extent of plaque increased with time and was statistically
associated with older age of the recipient, cigarette
smoking, hyperphosphatemia, hypoalbuminemia, longer
duration of pretransplant dialysis and the presence of
femoral plaque. The severity of the plaque also increased
with time and was statistically associated with age,
h y p e r t e n s i o n ,  m e t a b o l i c  a c i d o s i s  a n d
hyperphosphatemia. Somewhat surprisingly it was found
that the contralateral carotid plaque progressed
independently. Despite an association between
progression and impaired renal transplant function, the
independent nature of progression in the two carotids
implied that local rather than systemic factors were of
overriding importance once disease was established.
Cerebrovascular events were rare, in that they occurred
in only four patients, and did not appear to be related to
the severity of disease in the carotids. Despite an
increasing severity of internal carotid artery plaque, the
peak systolic flow ratio in the internal to common carotid
arteries, remained stable using duplex scanning. This
suggested that the growth of plaque during the period of
follow-up in this study was insufficient to encroach
significantly on the lumen cross-sectional area. In
contrast to the factors that were associated with disease,
it was surprising to find that glucose control, systemic
insulin levels, serum lipid levels, duration of diabetes
and cyclosporine dose were not associated with these
measures of vascular disease.
The implications of this study are that controlled trials
of prevention and treatment strategies are required in
transplant populations, especially after SPK, since it may
not be relevant to extrapolate from the non-uremic,
diabetic population.
Fertility
Female has low fertility after the onset of ESRF,
especially in patients with IDDM. Following renal
transplantation in nondiabetic patients, fertility may
return and many children have been successfully
delivered. SPK transplantation provides additional
problems because of the location of the grafts. Four males
have become fathers after SPK transplants at Westmead
and one female became pregnant 2 years after the
transplant (29). She was electively admitted at 30 weeks
and Cesarian Section performed at 34 weeks. The last 4
weeks of gestation were complicated by hypertension
and by graft pancreatitis which appeared to relate to
physical compression by the gravid uterus. The Cesarian
Section was hampered by the need to mobilize the
indurated pancreas in order to gain access to the lower
segment of the uterus. A healthy male infant weighing
1770 g was delivered with an Apgar score of seven at 1
minute and nine at 5 minutes. He and his mother were
discharged from hospital and both remained well with
normal renal and pancreatic function.
There have been 19 cases of pregnancies after SPK
reported in the literature (30,31), which have been
successful despite the long maternal history of diabetes,
physical relationship of the uterus and pancreas
transplant, and immunosuppressive medication. SPK
transplantation may become the treatment of choice for
diabetic patients with chronic renal failure wishing to
undertake a pregnancy.
CONCLUSION
The Westmead transplant program has demonstrated that
SKP transplantation yields a technically successful result
in comparison to the alternative of kidney transplantation
alone. In Australian patients with IDDM and ESRF, the
treatment of choice is to undergo SPK transplantation
before the need for dialysis and before the development
of severe neuropathy. Diabetic retinopathy must have
been adequately treated by laser photocoagulation and
the ideal patient will be young and normotensive, with
no pre-existing carotid or femoral atherosclerotic plaque.
This approach may, for a small proportion of patients
with ESRF and IDDM, return their prognosis to that of
the  non-diabet ic .  Development  of  pancreas
transplantation, no matter how effective and successful,
will always be limited by the number of cadaveric organs
available to two log orders of magnitude less than
required to treat all type 1 diabetics. Hence, if
transplantation is to provide a cure for all patients with
diabetes, it will only be through the provision of a
standardized islet xenograft or in vitro cultured human
islet graft.
REFERENCES
1. Disney APS, ed. ANZDATA Report 1996. Adelaide: ANZDATA
Registry, 1996.
2. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the
pancreas and duodenum along with the kidney in diabetic
nephropathy. Surgery 1967;61:827-831.
3. Lillehei RC, Simmons RL, Najarian JS, et al. Pancreatico-duodenal
allotransplantation: Experimental and clinical experience. Ann Surg
1970;172:405-436.
4. Sutherland DER, Gores PF, Farney AC, et al. Evolution of kidney,
pancreas, and islet transplantation for patients with diabetes at the
University of Minnesota. Am J Surg 1993;166:456-491.
5. Dubernard JM, Monti LD, Faure JL, et al. Report on 63 pancreas
and kidney transplants in uremic diabetic patients. Transplant Proc
1986;18:1111-1112.
6. Sollinger HW, Pirsch JD, De Alessandro AM, et al. Advantages of
bladder drainage in pancreas transplantation: a personal view. Clin
17
Hong Kong J Nephrol 1999;1(1):11-17. JR CHAPMAN, et al
Transplantation 1990;4:32-36.
7. Gruessner RWG, Sutherland DER. Simultaneous kidney and
segmental pancreas transplants from living related donors: the first
two successful cases. Transplantation 1996;61:1265-1268.
8. Chapman JR, Allen RDMA.ANZDATA Report 1996. ANZDATA
Registry. Disney APS (ed). Adelaide South Australia 62 -169.
9. Smets YFC, Westendorp RGJ, van der Pijl JW, et al. Effect of
simultaneous pancreas-kidney transplantation on mortality of
patients with type-1 diabetes mellitus and end stage renal failure.
Lancet 1999;353:1915-1919.
10. Jamison RL, Canaan-Kuhl S, Pratt R. Simultaneous kidney-
pancreas transplantation versus kidney transplantation alone:
patient survival, kidney graft survival, and post-transplant
hospitalization. Am J Kidney Dis 1992;20:61-67.
11. Douzdjian V, Abecassis MM, Corry RJ, et al. Simultaneous
pancreas-kidney versus kidney-alone transplants in diabetics:
increased risk of early cardiac death and acute rejection following
pancreas transplants. Clin Transplantation 1994;8:246-251.
12.Stratta RJ, Taylor RJ, Ozaki CF, et al. The analysis of benefit and
risk of combined pancreatic and renal transplantation versus renal
transplantation alone. SGO 1993;177:163-171.
13.Nankivell BJ, Chapman JR,Bovington KJ, O'Connell PJ, Allen RDM.
Glucose Homeostasis standards for pancreas transplantation. Clin
Transplantation 1998;12:434-438.
14.Nankivell BJ, Chapman JR, Bovington KJ, et al. Clinical
determinants  o f  g lucose homeostas is  a f ter  pancreas
transplantation. Transplantation 1996;61:1705-1711.
15.The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med 1993;329:977-986.
16.The Diabetes Control and Complications (DCCT) Research Group.
Effect of intensive therapy on the development and progression of
diabetic nephropathy in the Diabetes Control and Complications
Trial. Kidney Int 1995;47:1708-1720.
17.Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive
blood glucose control on late complications of type 1 diabetes.
Lancet 1993;341:1306-1309.
18.Chow VCC, Pai RP, Chapman JR, et al. Diabetic retinopathy after
combined kidney-pancreas transplantation. Clin Transplantation
1999. In press.
19.Allen RDM., Al-Harbi IS, Morris JGL, et al. Diabetic neuropathy
after pancreas transplantation: determinants of recovery.
Transplantation 1997;63:830-838.
20.Solders G, Persson A, Wilczek H. Autonomic system dysfunction
and polyneuropathy in non-diabetic uraemia. Transplantation
1986;41:616-619.
21.Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol
1993;50:536-539.
22.Kennedy WR, Navarro X, Sutherland DER. Neuropathy profile of
diabetic patients in a pancreas transplantation program. Neurology
1995;45:773-780.
23.Solders G, Tyden G, Persson A, Groth CG. Improvement of nerve
conduction in diabetic neuropathy: a follow-up study 4 years after
combined pancreatic renal transplantation. Diabetes 1992;41:946-
951.
24.Luke RG. Chronic renal failure: a vasculopathic state (editorial).
New Engl J Med 1998;339:799-805.
25.Raine AEG, Schwartz U, Ritz E. Hypertension and cardiac problems.
In: Davison AM, Cameron JS, Grunefeld JP, Kerr DNS, Ritz E,
Winearls CG, eds. Oxford Textbook of Nephrology, 2nd ed. Oxford:
Oxford University Press, 1998:1885-1918.
26. Ibels LS, Alfrey AC, Huffner WE, Craswell PW, Anderson JT, Weill
R. Arterial calcification and pathology in uraemic patients undergoing
dialysis. Am J Med 1979;66:790-796.
27.Foley RN, Parfrey PS, Harnett JD. Clinical and echocardiographic
disease in patients starting end-stage renal disease therapy. Kidney
Int 1995;47:186-192.
28.Nankivell BJ, Lau SG, Chapman JR, O'Connell PJ, Fletcher JP,
Allen RDM. Progression of macrovascular disease after
transplantation. Transplantation 1999. In press.
29.Karaitis LK, Lawrence S, Nichol MC, et al. Successful obstetric
outcome after simultaneous pancreas and kidney transplantation.
Med J Aust 1999;170:368-370.
30.Barrou BM, ruessner AC, Sutherland DER, Gruessner RWG.
Pregnancy after pancreas transplantation in the cyclosporine era.
Transplantation 1998;65:524-527.
31.Winter JTV, Ogburn PL, Ramin KD. Pregnancy after pancreatic renal
transplantation because of diabetes. Mayo Clin Proc 1997;72:1044-
1047.
